Kolexia
Baulac Michel Neurologie
Baulac Michel
Neurologie
Hôpital Pitie Salpetriere
Paris, France
128 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Épilepsie Crises épileptiques Épilepsies partielles Épilepsie temporale Sclérose Hippocampal Sclerosis Épilepsie généralisée Syndrome d'Unverricht-Lundborg État de mal épileptique

Collaborateurs

Voir plus
Navarro Vincent
Navarro Vincent
Hôpital Pitie Salpetriere, Paris, France
Dupont Sophie
Dupont Sophie
Hôpital Pitie Salpetriere, Paris, France
Adam Claude
Adam Claude
Hôpital Pitie Salpetriere, Paris, France
Clemenceau Stephane
Clemenceau Stephane
Hôpital Pitie Salpetriere, Paris, France

Industries

Voir plus
Zogenix International Limited
2 collaboration(s)
Dernière en 2021
LABORATOIRE X.O
1 collaboration(s)
Dernière en 2021
GW Research Limited
1 collaboration(s)
Dernière en 2020
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease (ULD) in Adolescents and Adults: A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Study to Evaluate the Efficacy and Safety of Brivaracetam Used as Adjunctive Treatment for 12 Weeks in Adolescent and Adult Patients (≥ 16 Years) With Genetically Ascertained Unverricht-Lundborg Disease
Essai Clinique (UCB)   03 mai 2023
Double-blind, Randomized Study Evaluating the Efficacy and Safety of Brivaracetam in Adults With Partial Onset Seizures: A Multi-center, Double-blind, Parallel-group, Placebo Controlled, Randomized Study: Evaluation of the Efficacy and Safety of Brivaracetam in Subjects (>= 16 to 70 Years Old) With Partial Onset Seizures.
Essai Clinique (UCB)   14 juillet 2022
Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam in Subjects Suffering From Epilepsy: An Open-label, Multicenter, Follow-up Trial to Evaluate Long-term Safety and Efficacy of Brivaracetam Used as Adjunctive Treatment at a Flexible Dose up to a Maximum of 200 mg/Day in Subjects Aged 16 Years or Older Suffering From Epilepsy
Essai Clinique (UCB)   16 août 2021
FDA Safety Warning on the Cardiac Effects of Lamotrigine: An Advisory From the Ad Hoc ILAE/AES Task Force.
Epilepsy currents   28 février 2021
FDA safety warning on the cardiac effects of lamotrigine: An advisory from the Ad Hoc ILAE/AES Task Force.
Epilepsia open   25 février 2021
SP0993: A Multicenter, Double-blind, Double-dummy, Randomized, Positive- Controlled Study Comparing the Efficacy and Safety of Lacosamide (200 to 600 mg/Day) to Controlled Release Carbamazepine (400 to 1200 mg/Day), Used as Monotherapy in Subjects (≥ 16 Years) Newly or Recently Diagnosed With Epilepsy and Experiencing Partial-onset or Generalized Tonic-clonic Seizures.
Essai Clinique (UCB)   15 janvier 2021
Safety, tolerability, and efficacy of brivaracetam as adjunctive therapy in patients with focal seizures, generalized onset seizures, or Unverricht-Lundborg disease: An open-label, long-term follow-up trial.
Epilepsy research   04 décembre 2020
Understanding the challenge of comparative effectiveness research in focal epilepsy: A review of network meta-analyses and real-world evidence on antiepileptic drugs.
Epilepsia   22 mars 2020
Loss-of-Function Mutations in NR4A2 Cause Dopa-Responsive Dystonia Parkinsonism.
Movement disorders : official journal of the Movement Disorder Society   10 janvier 2020
Conscious and unconscious expectancy effects: A behavioral, scalp and intracranial electroencephalography study.
Clinical neurophysiology : official journal of the International Federation of Clinical Neurophysiology   05 décembre 2019